Literature DB >> 12831291

Autoimmune bullous dermatoses in the elderly: diagnosis and management.

Diya F Mutasim1.   

Abstract

Elderly individuals are susceptible to autoimmune bullous dermatoses (in particular, pemphigoid, epidermolysis bullosa acquisita and paraneoplastic pemphigus). Bullous dermatoses are associated with high morbidity and mortality. Bullous dermatoses result from autoimmune responses to one or more components of the basement membrane or desmosomes. Pemphigoid results from autoimmunity to hemidesmosomal proteins present in the basement membrane of stratified squamous epithelia. Patients present with tense blisters in flexural areas of the skin. Mild or moderate bullous pemphigoid may be treated with potent topical corticosteroids while extensive disease usually requires systemic corticosteroids or systemic immunosuppressive agents such as azathioprine. Mucosal pemphigoid affects one or more mucous membranes that are lined by stratified squamous epithelia. The two most commonly involved sites are the eye and the oral cavity. Lesions frequently result in scar formation, which may cause blindness. Patients with severe disease or ocular involvement require aggressive therapy with corticosteroids and cyclophosphamide. Epidermolysis bullosa acquisita results from autoimmunity to type VII collagen in the anchoring fibrils of the basement membrane area. Lesions may either arise on an inflammatory base or be non-inflammatory and result primarily from trauma. The inflammatory type of the disease is more responsive to therapy than the non-inflammatory type. Treatment options include corticosteroids, dapsone, cyclosporin, plasmapheresis and immunoglobulin G. Paraneoplastic pemphigus results from autoimmunity to multiple antigens within the desmosomes. The disorder is associated with neoplasms, especially leukaemia and lymphoma. Patients present with severe stomatitis and polymorphous skin eruption. The mucosal and cutaneous involvement may respond to successful treatment of the underlying neoplasm or may require immunosuppressive therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12831291     DOI: 10.2165/00002512-200320090-00004

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  107 in total

Review 1.  Emerging treatment for epidermolysis bullosa acquisita.

Authors:  L Engineer; A R Ahmed
Journal:  J Am Acad Dermatol       Date:  2001-05       Impact factor: 11.527

2.  Benign mucous membrane pemphigoid. Response to therapy with cyclophosphamide.

Authors:  H J Brody; D J Pirozzi
Journal:  Arch Dermatol       Date:  1977-11

3.  Benign mucous membrane pemphigoid. An unusual case with electron microscopic findings.

Authors:  G J Brauner; K Jimbow
Journal:  Arch Dermatol       Date:  1972-10

4.  Minimizing cicatricial pemphigoid orodynia with minocycline.

Authors:  L Poskitt; F Wojnarowska
Journal:  Br J Dermatol       Date:  1995-05       Impact factor: 9.302

Review 5.  Cell adhesion molecules as targets of autoantibodies in pemphigus and pemphigoid, bullous diseases due to defective epidermal cell adhesion.

Authors:  J R Stanley
Journal:  Adv Immunol       Date:  1993       Impact factor: 3.543

6.  Direct immunofluorescence in oral lichen planus.

Authors:  G Laskaris; A Sklavounou; A Angelopoulos
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1982-05

Review 7.  Bullous and cicatricial pemphigoid. Clinical, histopathologic, and immunopathologic correlations.

Authors:  J R Person; R S Rogers
Journal:  Mayo Clin Proc       Date:  1977-01       Impact factor: 7.616

8.  Mucosal involvement in bullous and cicatricial pemphigoid. A clinical and immunopathological study.

Authors:  V A Venning; P A Frith; A J Bron; P R Millard; F Wojnarowska
Journal:  Br J Dermatol       Date:  1988-01       Impact factor: 9.302

9.  Epidermolysis bullosa acquisita--successful treatment with colchicine.

Authors:  M Megahed; K Scharffetter-Kochanek
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

10.  Azathioprine in treatment of bullous pemphigoid.

Authors:  M W Greaves; J L Burton; J Marks; R P Dawber
Journal:  Br Med J       Date:  1971-01-16
View more
  4 in total

Review 1.  Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes.

Authors:  Manuel Florian Struck; Peter Hilbert; Maja Mockenhaupt; Beate Reichelt; Michael Steen
Journal:  Intensive Care Med       Date:  2009-09-29       Impact factor: 17.440

Review 2.  Autoantigen complementarity: a new theory implicating complementary proteins as initiators of autoimmune disease.

Authors:  William F Pendergraft; Barrak M Pressler; J Charles Jennette; Ronald J Falk; Gloria A Preston
Journal:  J Mol Med (Berl)       Date:  2004-12-11       Impact factor: 4.599

3.  The effects of nicotinamide on reinstatement to cocaine seeking in male and female Sprague Dawley rats.

Authors:  Emily A Witt; Kathryn J Reissner
Journal:  Psychopharmacology (Berl)       Date:  2019-12-07       Impact factor: 4.530

4.  Autoimmune bullous dermatoses in the elderly: an update on pathophysiology, diagnosis and management.

Authors:  Diya F Mutasim
Journal:  Drugs Aging       Date:  2010-01-01       Impact factor: 3.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.